SOPHiA Genetics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

sophiagenetics.com

Founded Year

2011

Stage

IPO | IPO

Total Raised

$250.82M

Date of IPO

7/23/2021

Market Cap

0.27B

Stock Price

4.32

About SOPHiA Genetics

SOPHiA Genetics (NASDAQ:SOPH) is a health tech company which has developed SOPHiA AI, an advanced technology which accurately analyzes and detects all types of genomic variants to help clinicians better diagnose and treat their patients.

SOPHiA Genetics Headquarter Location

Rue du Centre 172

Saint Sulpice, 1025,

Switzerland

+41 21 694 10 60

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing SOPHiA Genetics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

SOPHiA Genetics is included in 8 Expert Collections, including Artificial Intelligence.

A

Artificial Intelligence

8,717 items

This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.

D

Digital Health 150

300 items

2019's cohort of the most promising digital health startups transforming the healthcare industry

M

Medical Devices

8,082 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

H

Health Monitoring & Diagnostics

2,394 items

Companies developing or offering products that aid in the assessment, screening, diagnosis, or monitoring of a person's state of health/wellness. Excludes companies focused solely on fitness/sports performance

O

Omics

1,265 items

Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data

D

Digital Health

12,800 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

SOPHiA Genetics Patents

SOPHiA Genetics has filed 16 patents.

The 3 most popular patent topics include:

  • Molecular biology
  • Genomics
  • DNA sequencing
patents chart

Application Date

Grant Date

Title

Related Topics

Status

6/5/2018

9/3/2019

Molecular biology, Genomics, Bioinformatics, Biological databases, Genetics

Grant

Application Date

6/5/2018

Grant Date

9/3/2019

Title

Related Topics

Molecular biology, Genomics, Bioinformatics, Biological databases, Genetics

Status

Grant

Latest SOPHiA Genetics News

Sophia Genetics Says New Product May Boost 2022 Revenues, Provides Project Updates

May 11, 2022

Premium Save for later CHICAGO – Sophia Genetics said this week that a new product may increase its 2022 revenues beyond current expectations as it counts on another recent release to meet current expectations. The firm also provided updates on a number of ongoing partnerships and projects. In connection with the release of its first quarter financial results on Tuesday, Sophia Genetics reiterated its previous 2022 revenue forecast, saying it "remains comfortable" with the low end of the predicted $51.5 million to $54.0 million range. However, Sophia said that those estimates do not take into account potential revenue from the forthcoming CarePath product, a multimodal analysis module for its flagship Data Driven Medicine (DDM) platform that represents the firm's first foray into clinical decision support. Sophia introduced CarePath at the JP Morgan Healthcare Conference in January and is on track to implement it in the second half of the year. "It's a pretty material upgrade for us," CFO Ross Muken said during a conference to discuss the financial results, adding that it makes the company into a true "data player." Muken noted that the company follows a consumption model, only recognizing revenue when a customer uses its platform. "We are not a traditional [software-as-a-service] model," he said. In its guidance, Sophia did consider potential revenues from a new deep learning-based application for detecting homologous recombination deficiency (HRD), a product that decentralizes HRD testing of tumor samples, enabling users to access Sophia's genomic analysis while retaining ownership of their data. Sophia, which has twin headquarters in Saint-Sulpice, Switzerland and in Boston, unveiled the HRD product in February at the same time it announced a collaboration with AstraZeneca to help European laboratories and research institutions conduct in-house HRD testing for ovarian cancer. Muken also said the company expects to see strong growth from central and specialty laboratories in the second half of the year. Sophia recently said that it signed a letter of intent with Ambry Genetics parent Realm IDx to codevelop novel genomic applications and commercialize multimodal applications to widen the use of next-generation sequencing for cancer care. Sophia CEO and Cofounder Jurgi Camblong said that the firm is in talks with several other central labs now, particularly around the HRD product. Muken suggested that a series of announcements would come in the second half of this year and into 2023. Camblong also said that the company extended its contract with Moffitt Cancer Center in Tampa, Florida, during Q1 and is "in the midst of signing an extension deal" with Brazilian clinical diagnostics giant Diagnosticos da America (DASA). Moffitt nearly tripled its volume of analytics use on the DDM platform in Q1, according to the company. Sophia had announced last month that it had passed 1 million profiles analyzed on the DDM platform, half of those in the past two years. Another project high on Sophia's priority list is DEEP-Lung IV , a multimodal study of metastatic non-small cell lung cancer that Sophia announced at the Radiological Society of North America conference late last year. The company is partnering with research institutions to conduct deep learning-based analysis of clinical, biological, genomic, and radiomic data to find and validate markers that might predict immunotherapy response. Camblong said that Roswell Park Comprehensive Cancer Center in Buffalo, New York, and two other organizations he did not name recently joined DEEP-Lung IV, bringing the total number of participating sites to 19 in seven countries. Seventeen sites have been activated so far and the study has recruited nearly 500 participants. The goal is to follow 4,000 patients at 30 sites worldwide. Sophia will provide an update on DEEP-Lung IV next month at the American Society for Clinical Oncology (ASCO) conference, Camblong said. The study is expected to continue through February 2024 . Also at ASCO, the company will have a joint presentation with GE Healthcare. Those firms formed an alliance last year to develop AI-driven analytics and workflow technologies for oncology, with an emphasis on matching treatments based on genomic profiles and cancer types. Initially, they are integrating data between the DDM platform and GE's Edison. Later, the firms will be engaging hospitals to bring together imaging and genomics data and also looking to develop multimodal analytics applications that draw from both technology platforms.

SOPHiA Genetics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

SOPHiA Genetics Rank

  • When was SOPHiA Genetics founded?

    SOPHiA Genetics was founded in 2011.

  • Where is SOPHiA Genetics's headquarters?

    SOPHiA Genetics's headquarters is located at Rue du Centre 172, Saint Sulpice.

  • What is SOPHiA Genetics's latest funding round?

    SOPHiA Genetics's latest funding round is IPO.

  • How much did SOPHiA Genetics raise?

    SOPHiA Genetics raised a total of $250.82M.

  • Who are the investors of SOPHiA Genetics?

    Investors of SOPHiA Genetics include Lakewood Midstream.

  • Who are SOPHiA Genetics's competitors?

    Competitors of SOPHiA Genetics include Genoox and 4 more.

You May Also Like

Owkin Logo
Owkin

Owkin specializes in AI technologies applied to clinical research with the aim of developing better drugs and treatments for patients. The company's purpose is to empower researchers in hospitals, universities and the biopharma industry to i) understand why drug efficacy varies from patient to patient, ii) improve the drug development process and iii) to help identify key drugs and treatments for each individual patient to improve patient outcomes. The company's precision medicine platform aims to enable medical insights for drug discovery and development by connecting life sciences firms with academic researchers and hospitals. The Owkin platform aims to enable partners to uncover siloed datasets while maintaining patient privacy and securing proprietary data using Federated Learning and innovative collaborative AI technology.

ConcertAI Logo
ConcertAI

ConcertAI specializes in integrated clinical RWD, AI solutions and outcomes science with a large RWD oncology dataset. ConcertAI develops a medical research tool suite that offers care-based oncology research and data analytics.

Tempus Logo
Tempus

Tempus builds a library of molecular and clinical data as well as a corresponding operating system for data accessibility and use. The company enables physicians to deliver personalized cancer care for patients through its interactive analytical and machine learning platform. It provides genomic sequencing services and molecular and therapeutic data analysis to empower physicians to make real-time, data-driven decisions.

Evidation Logo
Evidation

Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.

Data4Cure Logo
Data4Cure

Data4Cure’s CURIE turns vast amounts of genomic and clinical data into a continuously updated biomedical knowledge graph. Characterize disease. Predict sensitivity to drugs and drug combinations. Turn data into cures.

P
Plex Search

Plex Search is a cloud-based search engine that connects the scientific data. It analyzes all available data sets and returns the best answers to your question. It is based in ​Cambridge, Massachusetts.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.